StreetInsider.com News Articles

Form 6-K Evaxion A/S For: Oct 02

Fri, 02 Oct 2026 09:05:00 -0400

si-local-file:///var/storage/secattach/20261002/27139489.html

Evaxion to present EVX-01 cancer vaccine immune data at SITC 2026

Fri, 02 Oct 2026 09:01:17 -0400

Evaxion A/S (NASDAQ: EVAX) will present new immune data from its phase 2 trial of personalized cancer vaccine EVX-01 at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting in Phoenix, Arizona, scheduled for November 4-8, 2026.

The data will be presented in both an oral and poster session by Mads Lausen, Senior Scientist at Evaxion. The presentations will cover the systemic immunomodulatory effects of EVX-01 combined with pembrolizumab, beyond vaccine-specific T-cell responses, using comprehensive immune profiling.

EVX-01 is a personalized peptide-based cancer vaccine currently being evaluated in combination with Merck & Co.'s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in patients with advanced

Evaxion to present EVX-01 cancer vaccine immune data at SITC 2026

Fri, 02 Oct 2026 09:01:17 -0400

EVX-01 is a personalized peptide-based cancer vaccine currently being evaluated in combination with Merck & Co.'s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in patients with advanced

Evaxion will present new immune data for personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting

Fri, 02 Oct 2026 09:00:00 -0400

New immune data from the phase 2 trial with EVX-01 to be presented both in an oral and poster presentation
New data follows from the three-year clinical update for EVX-01 to be provided at the European Society for Medical Oncology (ESMO) 2026 congress on October 24, 2026

COPENHAGEN, Denmark, October 2, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, will present new immune data for AI-designed personalized cancer vaccine EVX-01 at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, taking place in Phoenix, Arizona,

Evaxion will present new immune data for personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting

Fri, 02 Oct 2026 09:00:00 -0400

New immune data from the phase 2 trial with EVX-01 to be presented both in an oral and poster presentation
New data follows from the three-year clinical update for EVX-01 to be provided at the European Society for Medical Oncology (ESMO) 2026 congress on October 24, 2026

Form 6-K Evaxion A/S For: Sep 14

Mon, 14 Sep 2026 08:05:00 -0400

si-local-file:///var/storage/secattach/20260914/27055761.html

Evaxion expands AI platform into autoimmune disease research

Mon, 14 Sep 2026 08:03:12 -0400

Evaxion A/S (NASDAQ: EVAX), a clinical-stage biotechnology company, announced it has begun applying its AI-Immunology™ platform to autoimmune diseases, expanding beyond its existing focus on cancer and infectious diseases.

According to a press release, the Copenhagen-based company is testing two treatment concepts: a tolerogenic vaccine approach and an autoantibody binder concept. The tolerogenic approach uses T-cell epitopes combined with immune modulators intended to direct the immune system toward tolerance. The autoantibody binder concept uses an antigen construct designed to capture autoantibodies, which the company describes as key drivers of tissue damage in many autoimmune conditions.

Evaxion states that initial experimental data from

Evaxion applies its AI-Immunology™ platform in autoimmune diseases

Mon, 14 Sep 2026 08:00:00 -0400

Autoimmune diseases are characterized by high unmet medical need with most current treatments only addressing symptoms. Evaxion will apply AI-Immunology™ to target underlying pathologies
The unique capabilities of AI-Immunology™ could potentially help develop new treatments with higher efficacy and less side effects than current treatments
Initial experimental data will be presented at the Protein & Antibody Engineering Summit (PEGS) Europe taking place in Lisbon, Portugal, on November 18, 2026

COPENHAGEN, Denmark, September 14, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI- Immunology™ platform, has begun the application of the platform in autoimmune diseases

Evaxion applies its AI-Immunology™ platform in autoimmune diseases

Mon, 14 Sep 2026 08:00:00 -0400

Autoimmune diseases are characterized by high unmet medical need with most current treatments only addressing symptoms. Evaxion will apply AI-Immunology™ to target underlying pathologies
The unique capabilities of AI-Immunology™ could potentially help develop new treatments with higher efficacy and less side effects than current treatments
Initial experimental data will be presented at the Protein & Antibody Engineering Summit (PEGS) Europe taking place in Lisbon, Portugal, on November 18, 2026

Form 6-K Evaxion A/S For: Aug 20

Thu, 20 Aug 2026 07:35:00 -0400

si-local-file:///var/storage/secattach/20260820/26952924.html

Form 6-K Evaxion A/S For: Aug 20

Thu, 20 Aug 2026 07:35:00 -0400

si-local-file:///var/storage/secattach/20260820/26952924.html

Evaxion posts $3.7M Q2 loss, advances cancer vaccine pipeline

Thu, 20 Aug 2026 07:31:13 -0400

Evaxion A/S (NASDAQ: EVAX), a Copenhagen-based clinical-stage vaccine company, reported a net loss of $3.7 million for the second quarter ended June 30, 2026, compared to a net loss of $4.8 million in the same period a year earlier, according to a company press release.

Research and development expenses were $2.3 million for the quarter, a slight increase from $2.2 million in the second quarter of 2025. General and administrative expenses fell to $1.5 million from $2.2 million in the year-ago period, primarily due to lower capital market costs. Cash and cash equivalents stood at $14.0 million as of June 30,

Form 6-K Evaxion A/S For: Jun 30

Thu, 20 Aug 2026 07:30:00 -0400

si-local-file:///var/storage/secattach/20260820/26952883.html

Form 6-K Evaxion A/S For: Jun 30

Thu, 20 Aug 2026 07:30:00 -0400

si-local-file:///var/storage/secattach/20260820/26952883.html

Evaxion announces business update and second quarter 2026 financial results

Thu, 20 Aug 2026 07:30:00 -0400

COPENHAGEN, Denmark, August 20, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, provides business update and announces second quarter 2026 financial results.

Business highlights (since last quarterly update)
Evaxion is making steady progress towards completing its strategic milestones for 2026. Highlights include:

Announcing the upcoming presentation of three-year clinical data for personalized cancer vaccine candidate EVX-01 at the ESMO Congress 2026
Presentation of new data for EVX-04, an off-the-shelf cancer vaccine for acute myeloid leukemia (AML)
Expansion and refocusing of our R&D pipeline with EVX-05, a

Evaxion announces business update and second quarter 2026 financial results

Thu, 20 Aug 2026 07:30:00 -0400

Business highlights (since last quarterly update)
Evaxion is making steady progress towards completing its strategic milestones for 2026. Highlights include:

Announcing the upcoming presentation of three-year clinical data for personalized cancer vaccine candidate EVX-01 at the ESMO Congress 2026
Presentation of new data for EVX-04, an off-the-shelf cancer vaccine for acute myeloid leukemia (AML)
Expansion and refocusing of our R&D pipeline with EVX-05, a

Form 6-K Evaxion A/S For: Aug 17

Mon, 17 Aug 2026 08:05:00 -0400

si-local-file:///var/storage/secattach/20260817/26935162.html

Form 6-K Evaxion A/S For: Aug 17

Mon, 17 Aug 2026 08:05:00 -0400

si-local-file:///var/storage/secattach/20260817/26935162.html

Evaxion adds brain cancer vaccine program, drops EVX-03

Mon, 17 Aug 2026 08:02:52 -0400

Evaxion A/S (NASDAQ: EVAX) announced the addition of EVX-05, a therapeutic vaccine candidate targeting glioblastoma, to its research and development pipeline, according to a company statement dated August 17, 2026.

EVX-05 is designed as an off-the-shelf vaccine targeting endogenous retrovirus-derived antigens shared among glioblastoma patients. The targets were identified using Evaxion's AI-Immunology platform. Evaxion is collaborating with Duke University School of Medicine on the program, with Professor Mustafa Khasraw and his team expected to conduct initial clinical testing.

Glioblastoma has an incidence rate of 3.19 per 100,000 persons in the United States, according to the National Institutes of Health. The New England

Evaxion adds brain cancer vaccine program, drops EVX-03

Mon, 17 Aug 2026 08:02:52 -0400

Glioblastoma has an incidence rate of 3.19 per 100,000 persons in the United States, according to the National Institutes of Health. The New England

Evaxion expands and refocuses R&D pipeline with EVX-05, an AI-designed off-the-shelf brain cancer vaccine program